Jan. 31 at 9:24 PM
Comm'l-stage oncology focused bio M&A history over the last 4 years. There have been an average of ~5 such transactions per year, or a little less than 1 every 2 months. While history is certainly not predictive of what will happen in the future, it appears apparent March through June is usually the busiest time. The last such transaction was announced at the end of September 2025 (4 months ago).
Just for fun, our educated guess around the most likely M&A candidates over the next few months:
$SNDX even though SNDX investors were disappointed an INCY transaction was not announced at JPM, it is still the most obvious considering obvious synergies.
$DAWN reported
$52.8MM in Ojemda product sales handily beating estimates of
$45.8MM at the time. Either DAWN exits via M&A or rolls the dice to overcome the herculean odds with DAY-301
$URGN the timing could not be better
$IOVA as we suspect the market has not priced in the lung data. IOVA ran to
$3 this week before pulling back.
$ZYME Jazz Pharma?
